Dianthus Therapeutics Inc expected to post a loss of 51 cents a share - Earnings Preview

Dianthus Therapeutics

30/10/2023 12:38

* Dianthus Therapeutics Inc  DNTH.OQ   DNTH.O  is expected
to show
a rise in quarterly revenue when it reports  results 
    * The Cambridge Massachusetts-based  company is expected to
report
revenue of $500 thousand, according to the estimate from one
analyst, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Dianthus
Therapeutics Inc
is for a loss of 51 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Dianthus
Therapeutics Inc is $34.5​, above​ its last closing price
of $11.90. ​​​

This summary was machine generated October 30 at 12:38 GMT.  All
figures in US dollars  unless otherwise stated